Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
От новых технологий производства к новым фармакотерапевтическим возможностям
От новых технологий производства к новым фармакотерапевтическим возможностям
Ю.П.Успенский, Е.В.Балукова. От новых технологий производства к новым фармакотерапевтическим возможностям. Consilium Medicum. Гастроэнтерология (Прил.). 2010; 2: .
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Мамедов М.Н. Руководство по диагностике и лечению метаболического синдрома. М.: Мультипринт, 2005; с. 13–24, 59–65.
2. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total cardiovascular disease mortality in middle-aged men. JAMA 2002; 4: 288 (21): 2709–16.
3. Буеверов А.О. Неалкогольный стеатогепатит. Методические рекомендации. 2005.
4. Лазебник Л.Б., Звенигородская Л.А. Метаболический синдром и органы пищеварения. М., 2009.
5. Полунина Т.Е., Маев И.В. Неалкогольный стеатоз печени в практике интерниста. Эффективная фармакотерапия в гастроэнтерологии. 2009; 1: 14–9.
6. Solis Herruzo JA, Garcia Ruiz I, Perez Carreras M, Munoz Yague MT. Non-alcoholic fatty liver disease. From insulin resistance to mitochondrial dysfunction. Rev Esp Enferm Dig 2006; 98 (11): 844–74.
7. Anfossi G, Massucco P, Bonomo K, Trovati M. Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits. Nutr Metab Cardiovasc Dis 2004; 14: 215–24.
8. Cohen LH, van Leeuwen RE, van Thiel GC et al. Equallypotent inhibitors of cholesterol synthesis in human hepatocytes have distinquishable effects on different cytochrome P 450 enzymes. Biopharm Drug Dispos 2000; 21: 353–64.
9. Shepherd J. Who should receive a statin these days? Lessons from recent clinical trials. J Intern Med 2006; 260: 305–19.
10. DaCosta KA, Cochary EF, Blusztajn JK et al. Accumulation of 1,20sn-diradylglycerol with increased membrane-associated protein kinase C may be the mechanism for spontaneous hepatocarcinogenesis in choline deficient rats. J Biol Chem 1993; 268: 2100–5.
11. USDA. Continuing Survey of food intakes by individuals, 1989–91. Washington, DC: United States Department of Agriculture, 1992.
12. Wurtman RT. Phosphatidylcholine in neurologic disorders. Presented at: Choline Phospholipids: Molecular Mechanisms for human disease. Satellite conference, University of North Carolina/American Institute of Nutrition; Friday, Apr. 3, 1992; San Diego, CA.
13. USDA. USDA Nationwide Food Consumption Survey, 1977–78. Washington, DC: United States Department of Agriculture, 1979.
14. Locker J, Reddy TV, Lombardi B. DNA methylation and hepatocarcinogenesis in rats fed a choline-devoid diet. Carcinogenesis 1986; 7: 1309–12.
15. Newberne PM, Rogers AE. labile methyl groups and the promotion of cancer. Am J Clin Nutr 1986; 6: 407–32.
16. Буеверов А.О., Ешану В.С., Маевская М.В., Ивашкин В.Т. Эссенциальные фосфолипиды в комплексной терапии стеатогепатита смешанного генеза. Клинич. перспективы гастроэнтерол., гепатол. 2008; 1: 17–22.
17. Zeisei SH, DaCosta KA, Franklin PD. Choline, an essencial nutrient for humans. FASEB J 1991; 5: 2093–8.
18. Sheard NF, Tayek JA, Bistrian BR et al. Plasma choline concentration in humans fed parenterally. Am J Clin Nutr 1986; 43: 219–24.
19. Buchman AL, Dubin M, Jenden D et al. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients. Gastroenterology 1992; 102: 1363–70.
20. Hsia SL, He JL, Mandel M, Froelich CW. Lowering serum cholesterol by topical treatment with soy phosphatidylcholine. Presented at: 7th International Congress on Phospholipids; Monday, Sep. 9, 1996; Brussels, Belgium.
21. Hsia SL, He JL, Nie Y et al. The hypocholesterolemic and antiatherogenic effects of topically applied phosphatidylcholine in rabbits with heritable hypercholesterolemia. Artery 1996; 22: 1–23.
22. O'Brien BC, Andews VG. Influence of dietary egg and soybean phospholipids and triacylglycerols on human serum lipoproteins. Lipids 1993; 28: 7–12.
23. Успенский Ю.П. Эссенциальные фосфолипиды: старые субстанции – новые технологические решения. Рос. журн. гастроэнтерол., гепатол., колопроктол. 2009; 5: 24–6.
2. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total cardiovascular disease mortality in middle-aged men. JAMA 2002; 4: 288 (21): 2709–16.
3. Буеверов А.О. Неалкогольный стеатогепатит. Методические рекомендации. 2005.
4. Лазебник Л.Б., Звенигородская Л.А. Метаболический синдром и органы пищеварения. М., 2009.
5. Полунина Т.Е., Маев И.В. Неалкогольный стеатоз печени в практике интерниста. Эффективная фармакотерапия в гастроэнтерологии. 2009; 1: 14–9.
6. Solis Herruzo JA, Garcia Ruiz I, Perez Carreras M, Munoz Yague MT. Non-alcoholic fatty liver disease. From insulin resistance to mitochondrial dysfunction. Rev Esp Enferm Dig 2006; 98 (11): 844–74.
7. Anfossi G, Massucco P, Bonomo K, Trovati M. Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits. Nutr Metab Cardiovasc Dis 2004; 14: 215–24.
8. Cohen LH, van Leeuwen RE, van Thiel GC et al. Equallypotent inhibitors of cholesterol synthesis in human hepatocytes have distinquishable effects on different cytochrome P 450 enzymes. Biopharm Drug Dispos 2000; 21: 353–64.
9. Shepherd J. Who should receive a statin these days? Lessons from recent clinical trials. J Intern Med 2006; 260: 305–19.
10. DaCosta KA, Cochary EF, Blusztajn JK et al. Accumulation of 1,20sn-diradylglycerol with increased membrane-associated protein kinase C may be the mechanism for spontaneous hepatocarcinogenesis in choline deficient rats. J Biol Chem 1993; 268: 2100–5.
11. USDA. Continuing Survey of food intakes by individuals, 1989–91. Washington, DC: United States Department of Agriculture, 1992.
12. Wurtman RT. Phosphatidylcholine in neurologic disorders. Presented at: Choline Phospholipids: Molecular Mechanisms for human disease. Satellite conference, University of North Carolina/American Institute of Nutrition; Friday, Apr. 3, 1992; San Diego, CA.
13. USDA. USDA Nationwide Food Consumption Survey, 1977–78. Washington, DC: United States Department of Agriculture, 1979.
14. Locker J, Reddy TV, Lombardi B. DNA methylation and hepatocarcinogenesis in rats fed a choline-devoid diet. Carcinogenesis 1986; 7: 1309–12.
15. Newberne PM, Rogers AE. labile methyl groups and the promotion of cancer. Am J Clin Nutr 1986; 6: 407–32.
16. Буеверов А.О., Ешану В.С., Маевская М.В., Ивашкин В.Т. Эссенциальные фосфолипиды в комплексной терапии стеатогепатита смешанного генеза. Клинич. перспективы гастроэнтерол., гепатол. 2008; 1: 17–22.
17. Zeisei SH, DaCosta KA, Franklin PD. Choline, an essencial nutrient for humans. FASEB J 1991; 5: 2093–8.
18. Sheard NF, Tayek JA, Bistrian BR et al. Plasma choline concentration in humans fed parenterally. Am J Clin Nutr 1986; 43: 219–24.
19. Buchman AL, Dubin M, Jenden D et al. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients. Gastroenterology 1992; 102: 1363–70.
20. Hsia SL, He JL, Mandel M, Froelich CW. Lowering serum cholesterol by topical treatment with soy phosphatidylcholine. Presented at: 7th International Congress on Phospholipids; Monday, Sep. 9, 1996; Brussels, Belgium.
21. Hsia SL, He JL, Nie Y et al. The hypocholesterolemic and antiatherogenic effects of topically applied phosphatidylcholine in rabbits with heritable hypercholesterolemia. Artery 1996; 22: 1–23.
22. O'Brien BC, Andews VG. Influence of dietary egg and soybean phospholipids and triacylglycerols on human serum lipoproteins. Lipids 1993; 28: 7–12.
23. Успенский Ю.П. Эссенциальные фосфолипиды: старые субстанции – новые технологические решения. Рос. журн. гастроэнтерол., гепатол., колопроктол. 2009; 5: 24–6.
Авторы
Ю.П.Успенский, Е.В.Балукова
Санкт-Петербургская государственная медицинская академия им. И.И.Мечникова
Санкт-Петербургская государственная медицинская академия им. И.И.Мечникова
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.